Small Molecules in Oncology from Emerging Companies: 2021’s IPOs Pt. III

This article is Part 3 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 2 provided an overview of 2021 IPOs by therapeutic area.

This short article takes a deeper look into the 2021 IPOs for conventional small molecules being developed by oncology-focused companies including:

  • Companies by asset class of focus and primary indication
  • Lead molecules, mechanisms of action, and structures where available
  • Development stage at IPO
  • IPO proceeds
  • A company spotlight

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from